MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

A Gomez-Iturriaga; D Büchser; I San Miguel; M Marban; A Urresola; A Ezquerro; A Gil; F Suarez; A Gonzalez; E Mairata; L Martinez-Indart; J Cacicedo; F Couñago; P Mínguez; F Casquero

doi:10.1016/j.ctro.2020.08.002

MRI detected extaprostatic extension (EPE) in prostate cancer: Do all T3a patients have the same outcomes?

Clin Transl Radiat Oncol. 2020 Aug 13:24:135-139. doi: 10.1016/j.ctro.2020.08.002. eCollection 2020 Sep.

Authors

A Gomez-Iturriaga¹, D Büchser¹, I San Miguel¹, M Marban^{1

1}, A Urresola¹, A Ezquerro¹, A Gil¹, F Suarez¹, A Gonzalez¹, E Mairata¹, L Martinez-Indart², J Cacicedo¹, F Couñago³, P Mínguez¹, F Casquero¹

Affiliations

¹ Hospital Universitario Cruces/Biocruces Bizkaia Health Research Institute, Radiation Oncology, Barakaldo, Spain.
² Hospital Universitario Cruces/Biocruces Health Research Institute, Clinical Epidemiology Unit, Barakaldo, Spain.
³ Department of Radiation Oncology, Hospital Universitario Quirón salud Madrid, 28223 Pozuelo de Alarcón, Madrid, Spain.

Abstract

MRI-detected T3a prostate cancer is a heterogeneous disease. This post-hoc analysis of a prospective trial found that patients with T3a disease presenting obliteration of the recto-prostatic angle, contact-asymmetry of neuro-vascular bundle and periprostatic fat invasion, may be at higher risk of biochemical failure and metastases.

Keywords: Biochemical failure; Extraprostatic extension; Metastases; Multiparametric MRI; Prostate cancer; Radiotherapy.